Price
$11.25
Increased by +4.46%
Dollar volume (20D)
3.72 M
ADR%
4.82
Earnings report date
Aug 4, 2025
Shares float
21.62 M
Shares short
4.03 M [18.64%]
Shares outstanding
50.00 M
Market cap
550.00 M
Beta
-0.08
Price/earnings
N/A
20D range
8.33 11.82
50D range
7.90 11.82
200D range
7.88 11.82

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States.

It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).

The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.

It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI.

Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 12, 25 -0.17
Increased by +27.75%
-0.09
Decreased by -92.67%
Feb 24, 25 -0.05
Increased by +70.53%
-0.08
Increased by +39.86%
Nov 12, 24 -0.06
Increased by +65.29%
-0.23
Increased by +74.35%
Aug 5, 24 -0.28
Increased by 0.00%
-0.21
Decreased by -33.33%
May 13, 24 -0.24
Increased by +31.43%
-0.25
Increased by +4.00%
Feb 26, 24 -0.17
Decreased by -13.33%
-0.15
Decreased by -13.33%
Nov 7, 23 -0.17
Increased by +19.05%
-0.21
Increased by +19.05%
Aug 7, 23 -0.28
Decreased by -211.11%
-0.21
Decreased by -33.33%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 15.39 M
Increased by +6.10%
-13.58 M
Decreased by -16.42%
Decreased by -88.24%
Decreased by -9.72%
Dec 31, 24 18.75 M
Increased by +6.77%
-15.53 M
Decreased by -82.43%
Decreased by -82.79%
Decreased by -70.87%
Sep 30, 24 16.87 M
Increased by +7.49%
-12.70 M
Decreased by -41.88%
Decreased by -75.28%
Decreased by -31.99%
Jun 30, 24 14.26 M
Increased by +3.69%
-16.53 M
Decreased by -5.65%
Decreased by -115.94%
Decreased by -1.89%
Mar 31, 24 14.50 M
Increased by +39.22%
-11.66 M
Increased by +47.19%
Decreased by -80.42%
Increased by +62.07%
Dec 31, 23 17.57 M
Increased by +19.91%
-8.51 M
Increased by +40.31%
Decreased by -48.45%
Increased by +50.22%
Sep 30, 23 15.69 M
Increased by +26.04%
-8.95 M
Decreased by -100.98%
Decreased by -57.03%
Decreased by -100.77%
Jun 30, 23 13.75 M
Increased by +24.43%
-15.64 M
Decreased by -91.00%
Decreased by -113.79%
Decreased by -53.51%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY